Edgewise Therapeutics, Inc.EWTX

$36.81+1.99 (+5.72%)

NASDAQHealthcare24:00 UTC

Company snapshot

Market Cap

$4B

Mid-cap

+607%

2021 — today

10-Year Price

+34%

2021 — today

52-Week Range

$12.61$40.26

Current $36.81· 88%

Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.

Valuation in context

P/E ratio

-22.2

N/A

Not meaningful — company is unprofitable

P/B ratio

8.0

Near historic high

Near historic highs — last 10 years

FCF Yield

-3.8%

Historically high

Historically high relative to the last 10 years

Free · No credit card needed

Get alerted when EWTX is cheap

Set a free alert — we'll push you when P/E, yield, or other metrics cross a historical threshold.